A review of tickets determined there is slightly elevated complaint activity for the architect havab igg reagent, lot number 03402be00.Tracking and trending report review did not identify any related trends.A review of field data for the architect havab igg reagent was performed as well as a review of the performance for the likely cause lot, 03402be00.The review showed that the median and standard deviations to the cutoff of the negative population for the likely cause lot were within established baselines; therefore, the performance of lot 03402be00 was not found to be compromised.Manufacturing documentation was reviewed and no issues were identified.Additionally, labeling was reviewed and sufficiently addresses the customers issue.Based on the investigation, no systemic issue or product deficiency of the architect havab igg reagent was identified.Correction to section d11: concomitant medical products and therapy dates: serial corrected from 03m74-01 to (b)(4).
|